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Some time ago, we proposed a continuum-like view of the lineages open to
hematopoietic stem cells (HSCs); each HSC self-renews or chooses from the spectrum
of all end-cell options and can then “merely” differentiate. Having selected a cell lineage,
an individual HSC may still “step sideways” to an alternative, albeit closely related,
fate: HSC and their progeny therefore remain versatile. The hematopoietic cytokines
erythropoietin, granulocyte colony-stimulating factor, macrophage colony-stimulating
factor, granulocyte/macrophage colony-stimulating factor and ligand for the fms-like
tyrosine kinase 3 instruct cell lineage. Sub-populations of HSCs express each of the
cytokine receptors that are positively auto-regulated upon cytokine binding. Many years
ago, Waddington proposed that the epigenetic landscape played an important role in
cell lineage choice. This landscape is dynamic and unstable especially regarding DNA
methylation patterns across genomic DNA. This may underlie the receptor diversity of
HSC and their decision-making.
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INTRODUCTION
Waddington (1957), developed the idea that the developmental fates of cells are somehow shaped
by a continuous interplay between environmental influences and the actions of genes, which
he dubbed “epigenetics”. He offered a celebrated pictorial depiction of this mysterious process
(Waddington, 1957), in which embryonic cells and their progeny started their developmental
journeys through his metaphorical landscape on the rolling uplands, and from there they coursed
through a bifurcating series of steep-sided valleys, with little chance of sideways escape, and
emerged as the various types of differentiated cells.
Early fate maps of hematopoiesis similarly envisaged branching development, from one initial
hematopoietic stem cell (HSC) population, to the many types of differentiated blood and immune
cells, with the progeny of HSCs progressing stepwise through several binary and irreversible fate
choices until the various types of haematopoietic end-cells emerged. In this scenario, HSCs are
cells that are able to either self-renew or commit to differentiation and thereby give rise to all of
the blood and immune cell types. Haematopoietic progenitor cells (HPCs) are their progeny that
have “chosen” to differentiate. They include cells that are multipotent and that have a sub-set of
differentiation potentials, having undergone stepwise fate choices.
Since the late 1950s, “epigenetics” has since come to mean much more than Waddington’s
original mid-20th century abstraction, and it now encompasses all of the many more recently
discovered processes – such as DNA methylation and various modifications of histones – that
modulate the functional outputs of genes without altering their underlying sequences.
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Here we focus on how a HSC “choses” a particular pathway of
development, leaving aside the substantial body of information
on dormancy vs. self-renewal vs. differentiation per se. There
has been similar progress in our views of the development of –
and understanding of the complex relationships between – the
various HSC-derived cell lineages, and we now recognize that
the pathways to and functions of the multifarious hematopoietic
cell types are less strictly demarcated than was initially thought.
HSCs also give rise to many more end-cell types than we
would hitherto have expected (Brown et al., 2018a). There
has long been a tendency to view each kind of blood and/or
immune cell as having a particular (set of) physiological
role(s) and to define – and sometimes to sort – these
cells based on a particular pattern of cell surface markers.
However, this overlooks the degree to which many of the
populations share some phenotypic and functional attributes.
For example, B-lymphocytes, monocytes and dendritic cells are
morphologically very different but are closely developmentally
related (see below), and they all phagocytose and pinocytose
foreign antigens, and process them.
Recently, the use of new tools have provided much more
information about the characteristics of the individual cells
that make up the HSC and HPC populations. Using the
“index sorting” function of cell sorters, we can isolate single
cells that have a precisely defined surface phenotype and
then relate this to a variety of other characteristics – such
as the genes the cell expresses and the proteins it contains.
New technologies that include single cell mRNA sequencing
and single-cell mass-spectrometry have allowed investigators to
profile the genes expressed by a cell. Whilst these advances have
allowed investigators to obtain much more information about the
characteristics of an individual cell and a population of cells. The
question of particular interest is how does a cell arrive at, and
maintain, a particular phenotype.
The use of new approaches has revealed that HSCs and
multipotent HPCs are heterogeneous regarding the proteins they
express and their lineage predispositions. Knapp et al. (2018)
characterized the most primitive CD34+ hematopoietic cells
from human cord blood (CB). They analyzed the mass cytometry
data obtained from individually assessed CD3− CD34+ CD19−
CD11b− CD38− CD45RA− CD90+ CD49f+ cells (CD49f+
CB) revealing extensive heterogeneity in the levels of the 40
proteins examined. Index-sorted CD49f+ CB were lentivirus
barcoded and their lineage potentials examined by injecting
pools of transduced cells into irradiated mice. The lineage
content of clones varied widely. For 61 clones (at 30–38 weeks),
a few (8%) yielded cells of many lineages, 13% yielded a B
cell/granulocyte/macrophage mixture, 30% produced B cells,
36% gave rise to granulocytes and macrophages, and 13% only
engrafted transiently. Optimization of the reconstitution assay
to detect both lymphoid and myeloid outputs resulted in 8% of
clones yielding cells of many lineages, 27% a myeloid/lymphoid
mixture, 30% producing myeloid cells, 22% giving rise to
lymphoid cells, and 14% engrafted transiently. A caveat to this
heterogeneity of primitive CB cells is that they might be a
mixture of HSCs and committed cells. Even so and as below,
the cells that we best purify as HSCs, and as a particular
downstream population of cells, are truly heterogeneous in
various ways. Perhaps, this alleviates the need to delineate HSCs
vs. HPCs (as above) and instead there is merely a population
of blood cell precursors with various lineage affiliations and
other properties.
Paul et al. (2015) similarly examined the transcriptional
patterns of individual mouse bone marrow myeloid
progenitors, and assigned cells to one of seven groups
along a neutrophil/basophil/eosinophil/monocyte/dendritic
cell/erythrocyte/megakaryocyte spectrum. They sub-classified
their cells into 18 populations, with variable degrees of
lineage affiliation. Cells in adjacent groups were more similar,
whereas those at the extremes were quite distinct. We might
therefore visualize the differences between cell types as a
continuum (see later).
LINEAGE-AFFILIATION CAN BE
INITIATED AS EARLY AS WITHIN HSC
For many years, we assumed that sorting of cell populations by
means of the multiple surface markers designed to harvest either
HSC or various multipotent HPCs would yield a population of
cells that is both relatively homogeneous and mostly multipotent.
We presumed that a large proportion of these cells had
the potential – either when appropriately cultured or when
engrafted into irradiated recipients – to give rise to a wide
spectrum of hematopoietic cells. However, the recent availability
of information on the characteristics and lineage outputs from
individual HSCs/HPCs has led to a fundamental change in view.
For example, in one of the experiments mentioned above a
substantial proportion of the CD49+ CD34+ human CB cells
harvested as “primitive HPCs” only gave rise to B lymphocytes
in engrafted animals.
In keeping with lineage affiliation starting earlier than
previously thought, even in HSCs, human adult bone marrow
CD34+ cells are mainly cells with uni-potent myeloid or
erythroid potential alongside some multipotent progenitors.
There are few oligo-potent progenitor intermediates, though
fetal liver contains HPCs with megakaryocyte/erythroid/myeloid
and megakaryocyte/erythroid fates (Notta et al., 2016). If
lineage-affiliation occurs as early as within HSC, then their
progeny that we ring-fence by the use of surface markers
and view as a multipotent cells should be a mixture of cells
with each having a distinct lineage signature. Indeed, this is
the case for a population of mouse cells first described as
early progenitors with lymphoid and myeloid potential (EPLM)
(Balciunaite et al., 2005a). A “primitive” sub-population of
EPLM lacks expression of the markers Ly6D, SiglecH, and
CD11c and RNA sequencing of single cells revealed that they
really are a mixture of cells with either a myeloid, dendritic
cell or lymphoid signature; few have lymphoid and myeloid
potential (Alberti-Servera et al., 2017). For the Ly6D− SiglecH−
CD11c− population, lineage affiliations must have occurred
at an earlier stage of development, perhaps within HSCs.
However, Kauts et al. (2016) have argued that intermediate oligo-
potent populations are important for the production of adult
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mouse blood cells and that the embryo produces blood cells
without this need.
A PAIRWISE AND CONTINUUM-LIKE
MODEL FOR HEMATOPOIESIS
In 2009, we proposed a pairwise and continuum-like view
of the lineages open to the HSCs. A lack of arrows on the
diagram to show a preferred route (or routes) to each end-cell
type reflected our viewpoint that several binary and irreversible
choices do not underlie the development of end-cell types
(Ceredig et al., 2009). Instead, each HSC self-renews or chooses
from a spectrum of all of the end cell options – then can “merely”
differentiate (Figure 1). Similarly, a schematic representation of
the data obtained for single-cell proteome measurements for
differentiating human CD34+ CB cells indicates a landscape
topology with multiple directional paths emanating from the
most primitive HSCs (Knapp et al., 2019). Whilst HSC can
therefore affiliate directly to a single cell lineage, they and their
progeny remain versatile. They may still “step sideways” to
an alternative fate. Megakaryocyte-primed human HSCs can
“step sideways” to erythropoiesis and because of a common
dependence on the transcription factor (TF) GATA-1 there is a
“shared” trajectory (Psaila and Mead, 2019). In this scenario and
when cells deviate “sideways” from their chosen fate – their most
probable route – they tend to switch most readily to a path that
leads to their pairwise neighbors in a relatedness hierarchy (see
Figure 1 and below). For example, an individual HSC committed
to macrophage development is more likely to step sideways
to generate neutrophils or dendritic cells than give rise to
B-lymphocytes, though the degree of sideways -shuﬄing in vivo
is unknown. As cells move toward terminal differentiation, the
extent of change to lineage preference progressively narrows.
Initially, we placed the cell lineages next to one another
from the options available to bi-potent cell populations, as
revealed for bone marrow cells using semi-solid medium, and
the sets of options available to mouse and human oligo-potent
progenitors, as revealed in cell culture experiments (Brown et al.,
2007; Ceredig et al., 2009). Additionally, a particular lineage
ties to its pairwise partners regarding attributes they share early
during development, for example, their use of TFs, and shared
functional characteristics, as mentioned above. By definition, a
continuum does not have precise boundaries in keeping with
sharing and a gradual and continuous process of commitment
to an end-cell type. Velten et al. (2017) arrived at very similar
links between the cell lineages by constructing the developmental
trajectories for human HPCs from integrating single-cell RNA
sequence data with data from single cell cultures. They placed cell
lineages in the order B cell, monocyte/dendritic cell, neutrophil,
eosinophil/basophil/mast cell, megakaryocyte and erythrocyte
(Velten et al., 2017) (see Figure 1), arguing that HSC lineage
commitment is a continuous process.
HSCs and their progeny showing some degree of early lineage
affiliation are nevertheless still versatile. The development of
mouse progenitor thymocytes exemplifies cells that appear to
have made a lineage “choice” but are still able to divert to a
different end-cell fate. Double negative (DN) 1 and DN2 mouse
progenitor thymocytes have begun to arrange their T cell receptor
β genes and they progress through the later stages of T-cell
developmental in fetal thymus organ cultures. They are on their
way to becoming T cells but can still give rise to macrophages and
FIGURE 1 | A spectrum of fate options is available to hematopoietic stem cells. By contrast to the progeny of HSCs moving stepwise, through serial fate decisions,
to various cell-types each HSC chooses from a spectrum of all of the end cell options. The arrows indicate that for each lineage there are pairwise neighbors in a
relatedness hierarchy. HSCs and their progeny remain versatile because having selected a cell lineage they may still “step sideways” to an alternative, albeit closely
related, fate(s).
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natural killer cells (Porritt et al., 2004; Balciunaite et al., 2005b).
For functional macrophages, DN1 and DN2 were cultured on ST-
2 stromal cells and with interleukin (IL)-7. ST-2 cells produce
a low level of macrophage colony-stimulating factor (M-CSF)
and macrophage colonies from DN1 and DN2 thymocytes did
not occur when investigators used the M-CSF-non-secreting OP9
stromal cell line for support. Culture of DN1 and DN2 cells on
OP9 cells and in the presence of IL-7 and IL-2 led to functional
natural killer cells but this was not to any large degree dependent
on the presence of IL-7 (Balciunaite et al., 2005b). In both these
instances, the presence of a particular cytokine, M-CSF and IL-
2, was required to “divert” the lineage affiliation of progenitor
thymocytes, indicating an importance of cytokines to lineage
choice. We have argued that the range of cell types seen in
the colonies formed by HPCs dispersed in semi-solid medium
colonies reflect cells that are shuﬄing sideways because they are
out of their normal social environment regarding fate restriction
(Brown et al., 2018b).
Nestorowa et al. (2016) RNA sequenced more than 1600
single mouse HSCs and HPCs and then constructed expression
maps to reveal the HSC trajectories along the erythroid,
granulocytic/macrophage and lymphoid pathways. They
proposed broad trajectories with cells having the option of
moving to the left or right of a chosen developmental trajectory.
Similarly, Olsson et al. (2016) observed bi-potential patterns of
gene expression in their analysis of the lineage status of HPCs. For
example, granulocyte/macrophage progenitors (GMP) express
Gfi1 and Irf8 mRNAs at low levels and increase expression of
these genes during neutrophil and macrophage specification,
respectively. Olsson et al. (2016) argue that bi-lineage states and
bursts of alternative gene expression are an important feature of
cell-fate specification.
SOME HAEMATOPOIETIC CYTOKINES
INSTRUCT LINEAGE FATE
Sub-populations of HSCs express cytokine receptors that
associate with a particular cell lineage(s). Mouse HSCs express
the receptor for macrophage colony-stimulating factor (M-CSFR,
and termed CSF-1R and c-fms) at their cell surface (Kondo
et al., 2000; Mossadegh-Keller et al., 2013), and in particular
by 19% of LT-HSC and 23% of short-term reconstituting HSCs
(ST-HSC) (Mooney et al., 2017). Thirteen percent and 19% of
mouse LT-HSC and ST-HSC, respectively, express mRNA for the
erythropoietin receptor (EpoR); the lack of an antibody at the
time precluded the analysis of protein expression (Mooney et al.,
2017). Human HSCs are enriched within CD34+CD38−/dim
bone marrow cells and some of these cells express the EpoR, as
measured using biotinylated recombinant Epo and a streptavidin
conjugate (Shinjo et al., 1997). The ligand for the fms-like
tyrosine kinase 3 (Flt3L) is lympho/myeloid affiliated. The fms-
like tyrosine kinase 3 (Flt3) is expressed by 5% of mouse
LT-HSC and 8% of ST-HSC and post-treatment with Flt3L
the downstream ribosomal protein S6 is phosphorylated. One
percent of LT-HSCs and 3% of ST-HSCs co-express Flt3 and
the M-CSFR and co-expression of the mRNAs encoding Flt3
and EpoR was rare (Mooney et al., 2017). Mobilization studies
using chimeric mice reconstituted with cells from wild type
and mice deficient in the receptor for granulocyte colony-
stimulating factor (G-CSFR) have shown that transplantable
HSCs express this receptor (Liu et al., 2000), and granulocyte-
colony stimulating factor (G-CSF) increases the frequency of
HSCs in bone marrow (Schuettpelz et al., 2014). Primitive
mouse HSCs express low to moderate levels of the receptor for
granulocyte/macrophage colony-stimulating factor (GM-CSF)
(Kondo et al., 2000). A sub-set of human CD34+CD38−/dim
bone marrow cells expresses the thrombopoietin receptor (TpoR)
(Ninos et al., 2006) and the platelet-associated von Willebrand
factor and biased toward the platelet and myeloid pathways
(Sanjuan-Pla et al., 2013). Thrombopoietin (Tpo) has a role in
maintaining HSC (De Graaf and Metcalf, 2011) and is essential
to maintain the TpoR+ sub-set.
Erythropoietin (Epo) supports erythroid progenitor cells
(Koury and Bondurant, 1990); G-CSF supports granulocyte
precursors (Demetri and Griffin, 1991; Metcalf, 1993); M-CSF the
development of macrophages and DCs (Hume and MacDonald,
2012) and GM-CSF precursors of granulocytes and macrophages
(Gasson, 1991; Metcalf, 1993). For many years, we therefore
viewed these cytokines as regulators of HPC survival and
proliferation (Cross et al., 1997). We now know they are
instrumental in determining HSC/HPC erythroid, granulocyte
and macrophage fates (Figure 2; reviewed in Brown et al., 2018b).
Epo commits multipotent mouse HPCs to the erythroid fate,
initiating a program that includes the expression of the erythroid-
affiliated TF GATA1 (Grover et al., 2014). In 1982, Metcalf and
Burgess cultured each of the daughter cells of mouse granulocyte-
macrophage colony forming cells in either GM-CSF or M-CSF
leading to the generation of granulocytes and macrophages,
respectively (Metcalf and Burgess, 1982). Continuous in vivo
tracing of cells provided proof that cytokines can instruct a choice
between the granulocyte and macrophage fates whereby Rieger
et al. (2009) showed that G-CSF and M-CSF instruct mouse
granulocyte/macrophage progenitors to adopt the granulocyte
and macrophage pathways, respectively. Single cell studies have
shown that M-CSF instructs myeloid lineage fate in mouse HSCs
including expression of the TF PU.1, a regulator of myeloid
development (Mossadegh-Keller et al., 2013).
The instructive action of Flt3L is concentration dependent.
Mouse HSC lie within populations of bone marrow cells
lacking expression of cell lineage markers (Lin−) and that
express the Sca-1 (Ly6 family) antigen and the receptor
for the stem cell factor CD117 or c-kit; and termed LSK.
Exposure of LSKs to Flt3L above a certain threshold level
drives their development along the myeloid-lymphoid pathways
and suppresses the generation of megakaryocyte and erythroid
progenitors (Tsapogas et al., 2014). Similarly, over-expression
of Flt3 in megakaryocyte/erythroid progenitors led to these
cells differentiating toward granulocytes and macrophages, and
upregulation of PU.1 (Onai et al., 2006).
An instructive vs. a permissive action of Flt3L on HPCs is also
highly cell type dependent. CLPs and EPLMs are downstream of
LSKs and Flt3L plays a permissive role during the development of
these cells along the B cell lineage (von Muenchow et al., 2016). In
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FIGURE 2 | Some of the haematopoietic cytokines instruct the lineage fate of haematopoietic stem and progenitor cells. Erythropoietin (Epo), granulocyte
colony-stimulating factor (GSF)/granulocyte/macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) instruct
hematopoietic stem cells (HSCs)/hematopoietic progenitor cells (HPCs) to adopt erythroid, neutrophil and macrophage fates, respectively. Above a certain threshold
level, the ligand for the fms-like tyrosine kinase 3 (Flt3L) drives HSC development along the myeloid-lymphoid pathways as opposed to the generation of
megakaryocyte and erythroid progenitors.
other words, FLt3L is essential for the survival and proliferation
of cells that are already committed to the B cell lineage.
Concentration and cell context are both important for
cytokine action and therefore survival/proliferation vs.
instructive actions of cytokines are not binary alternatives
per se. Low levels of multiple cytokines during steady state
conditions are sufficient to sustain cell survival/proliferation
and the steady-state production of blood cells in normal
ratios. By contrast, studies showing cytokines to be instructive
have exposed cells to a much higher level, as required for the
instructive action of FLt3L. Cytokine levels increase substantially
locally and systemically, for example, during an infection, which
might influence the lineage output of HSCs/HPCs by instructing
lineage fate. The hematopoietic and immune system therefore
respond to an emergency in the most appropriate manner.
As to filling in the gaps on identifying instructive
cytokines, there are at least 33 cytokines and over 100
genes that encode cytokine-like activities (Dinarello, 2007).
The emergence of adaptive immunity has been a major
driver to the evolution of this substantial array of cytokines
because their evolution parallels that of the immune system
(Liongue et al., 2016).
SHARING OF INTRACELLULAR
SIGNALING PATHWAYS
It seems unlikely that a unique intracellular signal(s) generated
by an instructive cytokine receptor encrypts specificity to
the choice of pathway. Replacement of the cytoplasmic and
signaling domain of the G-CSF receptor with the EpoR
signaling domain and expression of this chimeric receptor in
homozygous mice did not specify signals to skew hematopoiesis
toward erythropoiesis (Semerad et al., 1999). On the contrary,
the activation of different transduction pathways supports
erythropoiesis (reviewed in Constantinescu et al., 1999),
including the phosphoinositol-3 kinase (PI3-K)/Akt, Erk/MAPK
and JAK–STAT pathways, and protein tyrosine phosphatases
(Richmond et al., 2005). Signaling by the PI3-K/mitogen-
activated kinase (MAP) pathway is sufficient, but is not essential,
for erythroid differentiation because a mutant EpoR lacking
the phosphorylated tyrosine that recruits the p85 subunit
of PI3-K kinase, leading to activation of the MAP kinase
(ERK2) pathway, adequately supports erythroid differentiation.
Furthermore, mutant EpoRs that active only some of the
proteins support erythropoiesis when expressed in EpoR−/−
progenitors. An argument in favor of specificity within signal
transduction is that Epo up-regulation of pre-erythroid gene
expression within LSKFlt3−CD150+ HSCs is dependent on
PI3-K activation whereas this is not the case for pre-myeloid
gene expression which was unaffected by PI3-K inhibition
(Grover et al., 2014).
There is shared usage of a “core” signaling network by the
cytokine receptor family, as for example activation of MAP kinase
by EpoR (Richmond et al., 2005), M-CSFR (Curry et al., 2008)
and Flt3 (Hayakawa et al., 2000; Figure 3). This is not too
surprising because the outputs must converge on controlling cell
survival and proliferation. However, binding of a cytokine to its
receptor leads to the increased expression of a lineage-affiliated
TF that reinforces receptor expression, as follows.
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FIGURE 3 | Schematic representation of some of the controls on cellular
phenotype. The receptors for erythropoietin (Epo) and for macrophage-colony
stimulation factor (M-CSFR) and the fms-like tyrosine kinase 3 (Flt3) can
instruct erythroid, macrophage and lymphoid/myeloid fates, respectively.
Receptors share the use of signaling pathways and there is redundancy in
their use. Various transcription factors, the colored shapes labeled 1, 2, 3, and
4, and their cofactors, the colored CF ovals, target and densely occupy
certain genomic regions that are important for the specification of a cellular
phenotype. PI3-K, phosphatidylinositol 3-kinase; MAP,
mitogen-activated kinase.
AUTO-REGULATION OF CYTOKINE
RECEPTORS
For many years, investigators have argued that the action
of a constellation of TFs across the genome underlies the
unique and shared usage of gene cassettes to specify a cell’s
fate (Figure 3). More than 50 TFs influence the nature of
HSCs and TFs and their cofactors are a densely connected
regulatory network as required to specify a cell’s phenotype
(reviewed in Wilson et al., 2011). Where TFs and cofactors
reside within cells is important, for example, EpoR signaling leads
to proteins translocating from the cytoplasm to the nucleus to
form DNA-binding complexes that recognize the c-fos promotor
(Finbloom et al., 1994).
Are there pivotal and master regulators of lineage
specification? As revealed by the use of PU.1-GFP mice,
M-CSF stimulated expression of PU.1 in some LT-HSC leads to
myeloid lineage specification (Mossadegh-Keller et al., 2013).
Similarly, PU.1 and GATA-1 activation mark the specification
of HSCs into myeloid/lymphoid vs. myeloid/erythroid lineages,
respectively (Arinobu et al., 2007). Dahl et al. (2003) have
argued that the level of PU.1 is important with the need for a
higher level for macrophage than for neutrophil development.
However, Hoppe et al. (2016) have shown that the protein ratios
of the myeloid/lymphoid-affiliated PU.1 and erythroid-affiliated
GATA-1 do not direct lineage choice, and merely reinforce pre-
existing myeloid and erythroid fates, respectively. The finding
that PU.1 levels change after myeloid lineage choice also refute
a PU.1/GATA-1 switch (Strasser et al., 2018). The shared rather
than the unique usage of TFs argues also against any particular
TF providing a “master” signal. However, this is commensurate
with placing cell lineages next to one another in the continuum
model (Figure 2) whereby TFs can promote the development of
adjacent cell types and suppress the development of a cell lineage
that lies on either side of a fate (Ceredig et al., 2009).
A feature of some of the cytokine receptors that we know
to be instructive is that their expression is positively auto-
regulated (Figure 4). M-CSF treatment of mouse HSCs, which
include cells that express M-CSFR, leads to the expression of
PU.1 and genes for myeloid development. PU.1 also activates
the M-CSFR promotor to auto-regulate increased expression of
this receptor (Brach et al., 1991; Zhang et al., 1994; Stanley
and Chitu, 2014). Additionally, PU.1 controls expression of the
GM-CSFR, for neutrophil fate, and the G-CSFR (Smith et al.,
1996) that can instruct neutrophil fate. Another regulator of
G-CSFR is the CCAAT/enhancer binding protein (C/EBP) α -
a neutrophil-affiliated TF whereby loss of C/EBPα leads to loss
of myeloid programming (Hohaus et al., 1995; Smith et al.,
1996; Bereshchenko et al., 2009). Signaling from the G-CSF
receptor increases the expression of C/EBPα (Dahl et al., 2003)
FIGURE 4 | Auto and promiscuous regulation of the expression of cytokin
receptors. Macrophage-colony stimulating factor and granulocyte/
macrophage-colony stimulating factor/granulocyte-colony stimulating factor
can instruct macrophage and neutrophil fates, respectively.
Macrophage-colony stimulating factor receptor (M-CSFR) instruction of HSCs
leads to expression of the transcription factor PU.1. PU.1 in turn regulates
expression of the M-CSFR, the granulocyte/macrophage-colony stimulating
factor receptor (GM-CSFR) and the granulocyte-colony stimulating factor
receptor (G-CSFR). G-CSF receptor signaling increases the expression of
C/EBPα that regulates the expression of the GM-CSFR and the G-CSFR.
A complex interplay between transcription factors and the expression of
cytokine receptors might underlie meta-stable bi-lineage cell states and allow
HSCs that express the M-CSFR and cytokine stimulated to co-express
G-CSFR “side step” to an adjacent pathway (Figure 1).
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that supports neutrophil development. Like the M-CSFR, the
G-CSFR is auto-regulated by C/EBPα that also controls the
expression of the GM-CSFR that can also instruct neutrophil
fate. Activation of Flt3 expression needs cooperation between
MYB and C/EBPα (Volpe et al., 2015). Ligand-activation of Flt3
induces expression of both C/EBPα and PU.1 (Mizuki et al., 2003)
whereby Flt3 expression might be auto-regulated by C/EBPα,
expression of G-CSFR influenced by C/EBPα, and expression
of M-CSFR and GM-CSFR influenced by PU.1. This complex
interplay of cytokine receptors and TFs might underpin the
meta-stable bi-lineage states favored by Olsson et al. (2016) and
the near-neighbor arrangement of cell lineages in the pairwise
model (Figure 1). M-CSFR+ HSCs stimulated by M-CSF might
readily express G-CSFR to allow “side-ways” diversion to the
adjacent neutrophil pathway (Figure 1), and vice versa for
G-CSFR+ HSCs.
Does auto-regulation of gene expression play a more general
role in a cell’s capacity to change and/or establish its’ nature. The
most active metabolite of vitamin D 1α,25-dihydroxivitamin D3
binds to the vitamin D receptor, a TF, to drive the differentiation
of many types of cells. In mouse HSC-like cells, and many other
cell types, increased expression of the vitamin D receptor is auto-
regulated by its ligand (Janik et al., 2017). Every cell, with the
exception of erythrocytes, can produce a cytokine as well as
respond to them, and some cytokines function as a non-released
membrane protein (Dinarello, 2007). Human haematopoietic cell
lines representing early myeloid cells co-express Flt3 and Flt3L,
allowing self-determination of receptor activation to possibly
drive differentiation (Brasel et al., 1995). A cytokine-mediated
autocrine loop can also control activation of the M-CSFR (Menke
et al., 2012), the G-CSF (Mueller et al., 1999) and the GM-CSFR
(Rogers et al., 1994). Auto-regulation might therefore underlie
the established expression of some lineage-affiliated genes as seen
in global analyses.
THE EPIGENETIC LANDSCAPE AND
GENOMIC VARIABILITY
Various TFs target and densely occupy specific genomic regions
and sites poorly occupied by TFs contain genes expressed at low
level or absent expression (Figure 3; Chen et al., 2008). A different
viewpoint is that cells might compartmentalize regions of
chromatin with a particular degree of intrinsic noise. Chromatin
re-modeling is central to both these possibilities and TFs play a
role in this process. PU.1 has a PEST domain involved in protein-
protein interactions and DNA methytransferases are among the
many different partners (van Riel and Rosenbauer, 2014). PU.1
forms a complex with the de novo DNA methyltransferases
Dnmt3a and Dnmt3b (Suzuki et al., 2006) and the PU.1-
DNMT3b complex exists as monocytes differentiate to osteoclasts
(de la Rica et al., 2013). We view histone tail acetylation
as a means of opening chromatin. PU.1 binds the histone
acetyltransferases CREB-binding protein and p300 (Yamamoto
et al., 1999; Bai et al., 2005) and a histone deacetylase complex
consisting of histone deacetylase 1 and mammalian Sin3a
(Kihara-Negishi et al., 2001).
The landscape of the methylation status of regions of DNA
parallels the specific attributes of cells as revealed by sorting
primitive CD49f+ CB cells into six sub-populations, based
on their relative expressions of surface CD33, CD45, and
CD202b (TIE2): CD202b expression is a marker of long-term
repopulating mouse HSCs (LT-HSC). The CD33+CD90+ sub-
set contains all of the serial repopulating activity, as measured
by transfer into sub-lethally irradiated mice, and these cells are
also quiescent. Analysis of the DNA methylation profiles of
single index-sorted CD49f+ CB cells had revealed differential
methylation of regions of DNA regarding cell sub-sets and the
CD33+CD90+ CB cells have a distinct profile (Knapp et al.,
2018). They show a greater consistency in the methylation
status of DNA regions than any other sub-set. Importantly,
there was a significant relationship between differentially
methylated regions and the transcriptional signatures of the
CD33+CD90+ CB cells.
Histone modifications are important for fate specification
as follows. The chromatin of human CD34+ HPC is devoid of
the repressive histone mark H3K27me3 just after cell division.
Treatment of these cells with the instructive cytokines G-CSF/M-
CSF and Epo leads to the recruitment of the myeloid-affiliated
C/EBPα and lympho/myeloid-affiliated PU.1 vs. the erythroid-
affiliated GATA-1 to DNA. These TFs recruited to DNA just after
replication and blocking replication and increasing H3K27me3
levels suppressed cytokine driven differentiation (Petruk et al.,
2017). Moreover, Roy and Sridaran have used the pattern of
histone modifications to identify mouse cell types and their
relationship to one another. They examined the presence of
enhancer-enriched (H3K27ac, H3K4me1, and H3K4me2) and
promotor-enriched (H3K4me3) chromatin marks for 15 types of
haematopoietic cells. They used a clustering approach to identify
chromatin modules as a set of gene loci with the same activating
and repressive histone modifications. From modules that were
more or less similar between cells, they delineated closely and
distantly related cell types. Each group of the following cell types -
immature erythroid cells/mature erythroid cells, granulocyte-
macrophage progenitors/ macrophages/monocytes and
CD4/CD8 T lymphocytes - has marks that are more similar to one
another that to any other cell types (Roy and Sridharan, 2017).
Non-coding micro-RNAs (miRNAs) and long non-coding
RNAs (lncRNAs) are a further layer of epigenetic regulation
and include both enhancer and antisense RNAs. A substantial
amount of work deals with the role of non-coding RNAs in
orchestrating HSC differentiation, and the differentiation of other
cell types, that is outside the scope of this review. They are
important to modulating the behavior of cells because they
can interact simultaneously with many targets to alter the
expression of various components of TF networks and signaling
pathways. Petriv et al. (2010) profiled miRNAs regarding the
developmental hierarchy of mouse haematopoietic cells and used
the information to infer the relationships between cell lineages
and the functional similarities of cells. Are there non-coding
RNAs that guide lineage fate? LncRNAs play a role in the
commitment of osteoblasts to adipocyte differentiation (reviewed
in Yoshioka and Yoshiko, 2017) and non-coding RNAs are
therefore possible triggers of cell fate.
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Importantly, the epigenome is highly dynamic and unstable.
In the case of human pluripotent stem cells, there is instability
and variation in the DNA methylation of a subset of
developmental genes and a postulate is that this confers a
growth/survival advantage (Lund et al., 2012). DNA methylation
patterns across genomic DNA are unstable because for sub-
cloned normal fibroblast cells they are highly variable which is
attributable to a low fidelity of inheritance of DNA methylation
(Xie et al., 2011). Genomic instabilities in genes that are
associated with development are important to evolutionary
changes (Zhao et al., 2010) and an argument in favor of instability
playing a role to diversify HSCs is one of ontogeny repeating
phylogeny. Randomness of the epigenetic code, via stochastic
methylation changes (Laird et al., 2004; Riggs and Xiong, 2004),
might allow HSCs/HPCs to establish inter-individual variation in
lineage options (as above), providing the basis for the openness
of lineage options and cell decision-making.
“CHOOSING” A FATE AND
SURVIVABILITY
Whilst it is reasonable to accept that some cytokines drive
lineage choice, cells must presumable express the gene encoding
the receptor independently of the presence of the cytokine.
Two aspects to this matter are how and why does this
happen. As to how, a 1990s view of hematopoiesis focussed
on the promiscuous and low-level expression of genes by
HPCs. Expression of genes that are characteristic of different
lineages led to the so-called “priming” of various developmental
pathways (Cross and Enver, 1997; Enver and Greaves, 1998).
We do not understand what controls this promiscuity and
particularly its level. However, the genes primed in early human
CD34+CD38− HPCs included SCL, which regulates expression
of the receptor for stem cell factor (SCFR) (Lécuyer et al.,
2002), and PU.1 (Cross and Enver, 1997), which regulates
the promotors of M-CSFR, G-CSFR, and GM-CSFR. Early
studies of single CD34+, lineage− murine bone marrow cells
observed co-expression of mRNA for the SCFR with that for
the M-CSFR, G-CSFR, GM-CSFR, or EpoR (Hu et al., 1997).
We might view HSCs/HPCs as one-and-the-same and a mosaic
of cells regarding their expression of the SCFR, for survival
as HSCs, together with one or more of the other cytokine
receptors (Figure 5).
The extent to which the nature of the molecular structure
of chromatin might underpin the promiscuity of HSCs is of
particular interest. Chromatin domains that have a bivalent
structure, termed bivalent chromatin domains, are important
to the lineage choices that are available to cells, with a
suggested role in maintaining pluripotency. These non-coding
elements comprise of regions H3 lysine 27 methylation within
which are smaller regions of H3 lysine 4 methylation. They
coincide within regions of the genome that encode low-
level expression of TFs that play key a role in development.
A proposal is that the domains silence genes in embryonic
stem cells but they are still “poised” and readily activated
(Bernstein et al., 2006).
Raff postulated that cytokine, and other social, controls on
cell survival select the fittest cells (Raff, 1992). Similarly, the
basis of many homeostatic processes that govern the contribution
of a cell type to a tissue/organism is competition between cells
for resource including survival factors and cell-cell interaction
(Johnson, 2009). The endeavor to survive applies to both
developing and mature cells. Around 50% of oligodendrocytes
in the developing rat optic nerve normally die, presumably due
to competition for limiting amounts of survival signals (Barres
et al., 1992). B lymphocyte survival in the periphery relates to the
number of competitors and the availability of a survival factor(s)
(McLean et al., 1997; Agenès, 2003).
As to why HSCs express lineage affiliated cytokine receptors
may relate to the fact that the cytokines primarily ensure cell
survival. A possible benefit of HSC individuality regarding the co-
expression of cytokine receptors is to enhance survivability in a
sporadically changing cytokine environment and/or competition
for residency in a niche. Investigators mostly use stem cell
factor (SCF), Tpo and Flt3 to ensure HSC survival in culture
(De Graaf and Metcalf, 2011), including the HSCs expressing
the M-CSFR+ (Mooney et al., 2017). However, SCF might
become scarce in vivo and M-CSF, as available, signal to a
SCFR+ M-CSFR+ HSC to up-regulate the low level of M-CSFR+
expression. Auto-regulation of this receptor ensures a cell
“knows” which receptor to up-regulate, to optimize a “winner”
survival status. The advantage of this is that cells can switch
back and forth between the two survival modes. Additionally,
we might expect a substantial local increase in the level of
M-CSF to guide M-CSFR+ HSC toward macrophages that are
then adapted and addicted to M-CSF for survival, including
M-CSF signaling control of glucose uptake (Chang et al., 2009).
In keeping with this cytokine-enforced selection, HSCs respond
to chronic and sustained erythroid stress, and sustained exposure
to high Epo levels in vivo, by displaying an erythroid progenitor
profile, thereby bypassing other options to replenish erythrocytes
(Singh et al., 2018).
How does choice arise in the first place regarding
priming/expression of, for example, either the M-CSFR or
the EpoR? Chromatin remodeling is indispensable for normal
hematopoiesis in mice and the development of both the myeloid
and lymphoid cell lineages (Han et al., 2019). The nascent
status of chromatin is important because there is engraving of
chromatin, including demethylation of CpG dinucleotides at
critical TF binding sites, prior to cell lineage specification (Tagoh
et al., 2004). What then drives the pattern of this landscape to
specify and/or sustain the choice of a lineage? As considered
above, perhaps inherent instability/lack of fidelity in the DNA
methylation pattern across genomic DNA and/or chromatin
activating and repressive histone modifications leads to the
generation of a pool of HSCs with individual lineage biases as to
a cytokine receptor(s) and a survival “winner” status.
IMPLICATIONS FOR LEUKEMIA
Whilst lineage affiliation can occur within HSCs, they
nevertheless remain versatile. Many leukemias and cancers
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FIGURE 5 | Haematopoietic stem and progenitors are a heterogeneous population of cells. (A) Subpopulations of haematopoietic stem and progenitor cells express
the receptors for the cytokines thrombopoietin (TpoR), erythropoietin (EpoR), granulocyte-colony stimulating factor (G-CSFR) and macrophage-colony stimulating
factor (M-CSFR) and the fms-like tyrosine kinase receptor (Flt3). A combination of stem cell factor (SCF), thrombopoietin and the ligand for Flt3 is sufficient to ensure
the survival of HSCs ex vivo. (B) M-CSF instructs myeloid lineage fate in HSCs and the expression of PU.1. PU.1 regulates the expression of M-CSFR and G-CSFR.
A local increase in M-CSF and autoregulation of M-CSFR expression might guide HSC toward a macrophage progenitor profile.
arise in a single stem cell and the malignant cells are forced
mostly down one developmental pathway. Sánchez-Garcia
and colleagues have argued that restriction of a leukemic
HSC to one pathway occurs by oncogenes orchestrating the
epigenome toward a leukemic cell lineage – with additional
oncogene insults then converting this cell into a leukemia stem
cell (LSC). Activity of the first oncogene is neither necessary
to maintain LSCs nor for disease progression (Brown and
Sanchez-Garcia, 2015; García-Ramírez et al., 2018; Vicente-
Dueñas et al., 2018; Vicente-Dueñas et al., 2019). Its role is to
focus HSC options into only one pathway, thus restricting LSCs
and their progeny to that pathway. In this model, oncogene-
restriction of the spectrum of options available to HSCs to
just one pathway/fate, in other words a loss of versatility, is
central to the initiation of leukemia. The oncogenic fusion
proteins are important. For example, the BCR-ABL and BCR-
ABLp210 oncogenes have roles in human leukemia and initiate
leukemia when the expression of each oncogene is restricted
to HSCs in transgenic mice. Each mouse line developed
B-lymphocyte and chronic myeloid leukemia, respectively,
typifying the human diseases (Brown and Sanchez-Garcia, 2015;
García-Ramírez et al., 2018).
The instructive action of cytokines and TF-mediated
auto-regulation of their receptors have implications to our
understanding of leukemia. PU.1 plays a role in the perturbation
in differentiation seen in acute myeloid leukemia (AML).
Heterozygous mutations of the PU.1 gene are found in
some AML patients and 7 of the 9 mutations identified
in 126 patients led to a deficiency in PU.1 binding to and
transactivation of the M-CSFR promotor (Mueller et al.,
2002). Mice with PU.1 alleles that reduce expression to
20% of the normal level accumulate abnormal precursors
that preserve responsiveness to G-CSF, for survival and
important to neutrophil fate, whereas responsiveness to
M-CSF and GM-CSF, for monocyte vs. neutrophil fate, is
disrupted (Rosenbauer et al., 2004). The link between PU.1
and epigenetic control is pertinent to PU.1 gene-mediated
perturbations in AML (see above) whereby re-setting or
switching-off epigenetic processes might provide an approach to
normalizing leukemia cells.
Mutations in the CEBPα gene occur in roughly 10% of
AML patients (Pabst and Mueller, 2009), but there is confusion
about whether CEBPα expression is low or high in patients’
cells (Pabst and Mueller, 2009; Gholami et al., 2019). Epigenetic
alterations of C/EBPα are a frequent event and epigenetic
treatments can lead to down-regulation of this TF (Hackanson
et al., 2008). Myb regulates Flt3 expression. One of the most
frequent translocations observed in AML is t(9;11) and the Myb
gene is up-regulated in cells from these patients (Lee et al.,
2006) and over-expression of Myb contributes to leukemogenesis
in human AML (K562)-SCID chimeric mice (Ratajczak et al.,
1992). Relatively small changes to the levels of these TFs might
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“set” the lineage fate of a LSC via a profound change to the level
of auto-regulated expression of a particular cytokine receptor(s).
PERSPECTIVES AND CONCLUSION
A cytokine-mediated instructive vs. a stochastic process, whereby
the cytokines are merely permissive for differentiation, is far
too simple a viewpoint of decision-making by HSCs/HPCs. It
is reasonable to conclude that both nature, the innate attributes
of cells, and nurture, by cytokines, play a role in specifying
the lineage fate of a cell. Epo, G-CSF, M-CSF, GM-CSF and
Flt3L can instruct cell lineage. Their receptors share use of
the known intracellular signaling pathways, but signaling does
lead to the expression of an appropriate lineage-affiliated TF(s).
There is little evidence for a “master” TF regulator, or mix,
for each of the individual cell lineages. However, the clustering
of a variety of TFs to chromosome regions is important and
innate instability to this landscape would endow individuality
within HSCs, including perhaps the variable expression of
cytokine receptors. In turn, receptors sensing a change in the
environment as to the presence or absence of a cytokine would
“guide” a cell toward a new identity. To commit to/arrive
at a new identity, there is regulation of distant cassettes of
genes and genome-wide mapping of TF binding events is
feasible, but this is descriptive. From all of the above, a
prediction is that the capture of chromatin signatures regarding
regulatory elements that lie outside the boundaries of a gene
locus coupled with information about the lineage intent of a
cell population will advance our understanding of decision-
making by HSCs.
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